PDB70 - ECONOMIC EVALUATION OF THE USE OF RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR (HEBERPROT-P®) AS AN ADJUVANT OF CONVENTIONAL THERAPY FOR THE TREATMENT OF DIABETIC FOOT ULCER

Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.775
https://www.valueinhealthjournal.com/article/S1098-3015(18)34075-0/fulltext
Section Title :
Section Order : 182
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)34075-0&doi=10.1016/j.jval.2018.09.775
HEOR Topics :
Tags :
Regions :